抗土拉菌病疫苗
Vaccines against tularemia.
作者信息
Barry Eileen M, Cole Leah E, Santiago Araceli E
机构信息
University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, USA.
出版信息
Hum Vaccin. 2009 Dec;5(12):832-8. doi: 10.4161/hv.10297. Epub 2009 Dec 11.
Abstract
Francisella tularensis is a Category A select agent for which vaccine and countermeasure development are a priority. In the past eight years, renewed interest in this pathogen has led to the generation of an enormous amount of new data on both the pathogen itself and its interaction with host cells. This information has fostered the development of various vaccine candidates including acellular subunit, killed whole cell and live attenuated. This review summarizes the progress and promise of these various candidates.
摘要
土拉弗朗西斯菌是一种A类生物制剂，疫苗和应对措施的研发是其首要任务。在过去八年里，对这种病原体重新燃起的兴趣催生了大量关于病原体本身及其与宿主细胞相互作用的新数据。这些信息推动了多种候选疫苗的开发，包括无细胞亚单位疫苗、灭活全细胞疫苗和减毒活疫苗。本综述总结了这些不同候选疫苗的进展和前景。
相似文献
1
Vaccines against tularemia.抗土拉菌病疫苗
Hum Vaccin. 2009 Dec;5(12):832-8. doi: 10.4161/hv.10297. Epub 2009 Dec 11.
2
Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent subsp. .减毒活土拉弗朗西丝菌疫苗对呼吸道感染强毒. 亚种的保护作用。
Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018.
3
Francisella tularensis vaccines.土拉弗朗西斯菌疫苗
FEMS Immunol Med Microbiol. 2007 Apr;49(3):315-23. doi: 10.1111/j.1574-695X.2007.00219.x. Epub 2007 Feb 22.
4
Live attenuated tularemia vaccines: recent developments and future goals.减毒活兔热病疫苗：近期进展与未来目标
Vaccine. 2013 Aug 2;31(35):3485-91. doi: 10.1016/j.vaccine.2013.05.096. Epub 2013 Jun 10.
5
Vaccines against Francisella tularensis--past, present and future.针对土拉弗朗西斯菌的疫苗——过去、现在与未来
Expert Rev Vaccines. 2004 Jun;3(3):307-14. doi: 10.1586/14760584.3.3.307.
6
Rationally designed tularemia vaccines.合理设计的兔热病疫苗。
Expert Rev Vaccines. 2009 Jul;8(7):877-85. doi: 10.1586/erv.09.51.
7
Tularemia vaccines: recent developments and remaining hurdles.兔热病疫苗：最新进展及尚存障碍。
Future Microbiol. 2011 Apr;6(4):391-405. doi: 10.2217/fmb.11.22.
8
Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).从脾脏、肝脏和肺部白细胞功能的体外分析中得出的模型可预测对土拉弗朗西斯菌活疫苗株（LVS）的疫苗效力。
mBio. 2014 Apr 8;5(2):e00936. doi: 10.1128/mBio.00936-13.
9
Francisella tularensis vaccines.土拉弗朗西斯菌疫苗
Vaccine. 2009 Nov 5;27 Suppl 4:D48-51. doi: 10.1016/j.vaccine.2009.07.090.
10
Tularemia vaccines.兔热病疫苗
Folia Microbiol (Praha). 2016 Nov;61(6):495-504. doi: 10.1007/s12223-016-0461-z. Epub 2016 May 19.
引用本文的文献
1
Development, Strategies, and Challenges for Tularemia Vaccine.土拉菌病疫苗的研发、策略及挑战。
Curr Microbiol. 2024 Apr 2;81(5):126. doi: 10.1007/s00284-024-03658-0.
2
Tularemia - a re-emerging disease with growing concern.兔热病——一种重新出现的疾病，引起了越来越多的关注。
Vet Q. 2023 Dec;43(1):1-16. doi: 10.1080/01652176.2023.2277753. Epub 2023 Nov 18.
3
Comparative evaluation of protective immunity against induced by subunit or adenovirus-vectored vaccines.诱导的保护性免疫的亚单位疫苗或腺病毒载体疫苗的比较评价。
Front Cell Infect Microbiol. 2023 May 25;13:1195314. doi: 10.3389/fcimb.2023.1195314. eCollection 2023.
4
Structural and biophysical properties of FopA, a major outer membrane protein of Francisella tularensis.弗氏志贺菌主要外膜蛋白 FopA 的结构和生物物理特性。
PLoS One. 2022 Aug 1;17(8):e0267370. doi: 10.1371/journal.pone.0267370. eCollection 2022.
5
Deletion Mutants of Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal LVS Challenge in a Murine Model of Respiratory Tularemia.吞噬体转运蛋白FptA和FptF的缺失突变体在毒力上高度减弱，并在呼吸道土拉菌病小鼠模型中对致死性鼻内LVS攻击具有保护作用。
Pathogens. 2021 Jun 24;10(7):799. doi: 10.3390/pathogens10070799.
6
Tularemia: a re-emerging tick-borne infectious disease.兔热病：一种再度出现的蜱传传染病。
Folia Microbiol (Praha). 2021 Feb;66(1):1-14. doi: 10.1007/s12223-020-00827-z. Epub 2020 Sep 28.
7
Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to .用基因修饰 O 抗原的糖缀合物疫苗诱导针对 的保护性抗体。
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7062-7070. doi: 10.1073/pnas.1900144116. Epub 2019 Mar 14.
8
An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.一种改良的抗呼吸道兔热病烟草花叶病毒（TMV）缀合多抗原亚单位疫苗。
Front Microbiol. 2018 Jun 5;9:1195. doi: 10.3389/fmicb.2018.01195. eCollection 2018.
9
Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.鼻腔内给予两剂佐剂多抗原 TMV-亚单位缀合疫苗可完全保护小鼠免受兔热病杆菌 LVS 挑战。
PLoS One. 2018 Apr 23;13(4):e0194614. doi: 10.1371/journal.pone.0194614. eCollection 2018.
10
Deletion of the Major Facilitator Superfamily Transporter Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis.主要易化超家族转运蛋白缺失改变了宿主细胞相互作用并减弱了 A 型土拉弗朗西斯菌的毒力。
Infect Immun. 2018 Feb 20;86(3). doi: 10.1128/IAI.00832-17. Print 2018 Mar.
本文引用的文献
1
Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.用A 型土拉弗朗西斯菌菌株对费希尔344大鼠进行肺部感染疫苗接种。
Vaccine. 2009 Jul 23;27(34):4684-93. doi: 10.1016/j.vaccine.2009.05.060. Epub 2009 Jun 9.
2
Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes.对guaA和guaB基因存在缺失的经合理减毒的土拉弗朗西斯菌疫苗菌株的特性分析。
Vaccine. 2009 Apr 21;27(18):2426-36. doi: 10.1016/j.vaccine.2009.02.073. Epub 2009 Mar 3.
3
Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.鉴定来自土拉弗朗西斯菌LVS的膜脂蛋白Tul4中的一个显性CD4 T细胞表位。
Mol Immunol. 2009 May;46(8-9):1830-8. doi: 10.1016/j.molimm.2009.01.008. Epub 2009 Feb 23.
4
DSB proteins and bacterial pathogenicity.双链断裂（DSB）蛋白与细菌致病性
Nat Rev Microbiol. 2009 Mar;7(3):215-25. doi: 10.1038/nrmicro2087. Epub 2009 Feb 9.
5
Glutathione provides a source of cysteine essential for intracellular multiplication of Francisella tularensis.谷胱甘肽为土拉弗朗西斯菌在细胞内增殖提供了必不可少的半胱氨酸来源。
PLoS Pathog. 2009 Jan;5(1):e1000284. doi: 10.1371/journal.ppat.1000284. Epub 2008 Jan 30.
6
Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.细胞免疫和体液免疫在抵御A型和B型土拉弗朗西斯菌方面具有协同作用。
Vaccine. 2009 Jan 22;27(4):597-605. doi: 10.1016/j.vaccine.2008.10.079. Epub 2008 Nov 18.
7
Identification of an essential Francisella tularensis subsp. tularensis virulence factor.鉴定土拉弗朗西斯菌兔热病亚种的一种必需毒力因子。
Infect Immun. 2009 Jan;77(1):152-61. doi: 10.1128/IAI.01113-08. Epub 2008 Nov 3.
8
The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression.土拉弗朗西斯菌的早期吞噬体阶段决定了最佳的吞噬体逃逸及土拉弗朗西斯菌致病岛蛋白表达。
Infect Immun. 2008 Dec;76(12):5488-99. doi: 10.1128/IAI.00682-08. Epub 2008 Oct 13.
9
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.一种用于预防由土拉热弗朗西斯菌SchuS4菌株引起的呼吸道兔热病的改良疫苗。
Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.
10
Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.脑膜炎奈瑟菌PorB，一种Toll样受体2配体，可提高土拉弗朗西斯菌脂多糖保护小鼠抵抗实验性兔热病的能力。
Clin Vaccine Immunol. 2008 Sep;15(9):1322-9. doi: 10.1128/CVI.00125-08. Epub 2008 Jul 9.
Zotero 插件